# PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Canonical URL: https://biopharmsignal.com/news/PRTC/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine
Ticker: PRTC
Company: PureTech Health
Source: PureTech Health
Published: 2026-04-02 11:00 EST
Original Source URL: https://investors.puretechhealth.com
## Summary

Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging First industry-sponsored IPF

## Article Body
Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging First industry-sponsored IPF
## Recent Company News
- 2026-05-13 11:00 EST — [PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference](https://biopharmsignal.com/news/PRTC/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference) — Source: PureTech Health
- 2026-05-01 06:00 EST — [PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-announces-pricing-of-upsized-initial-public-offering) — Source: PureTech Health
- 2026-04-29 06:01 EST — [PureTech Announces Annual Results for Year Ended December 31, 2025](https://biopharmsignal.com/news/PRTC/puretech-announces-annual-results-for-year-ended-december-31-2025) — Source: PureTech Health
- 2026-04-29 06:00 EST — [PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange](https://biopharmsignal.com/news/PRTC/puretech-announces-intention-to-voluntarily-delist-american-depositary-shares-from-nasdaq-and-concentrate-trading-on-the-london-stock-exchange) — Source: PureTech Health
- 2026-04-27 11:05 EST — [PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-adds-intra-cellular-therapies-founder-and-ceo-dr-sharon-mates-to-its-board-of-directors) — Source: PureTech Health
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)